Chronic expanding pituitary hematoma with calcification resulting from pituitary adenoma: illustrative case.

chronic encapsulated expanding hematoma endoscopic surgery pituitary adenoma pituitary apoplexy

Journal

Journal of neurosurgery. Case lessons
ISSN: 2694-1902
Titre abrégé: J Neurosurg Case Lessons
Pays: United States
ID NLM: 9918227275606676

Informations de publication

Date de publication:
06 Mar 2023
Historique:
received: 12 01 2023
accepted: 14 02 2023
entrez: 7 3 2023
pubmed: 8 3 2023
medline: 8 3 2023
Statut: epublish

Résumé

Pituitary apoplexy (PA) is characterized by sudden headache, vomiting, visual dysfunction, anterior lobe dysfunction, and endocrine disorder due to bleeding or infarction from a pituitary adenoma. PA occurs in approximately 0.6-10% of pituitary adenomas, more commonly in men aged 50-60 years, and more frequently in nonfunctioning and prolactin-producing pituitary adenomas. Further, asymptomatic hemorrhagic infarction is found in approximately 25% of PA. A pituitary tumor with asymptomatic hemorrhage was detected on head magnetic resonance imaging (MRI). Thereafter, the patient underwent head MRI every 6 months. After 2 years, the tumor was enlarged and visual dysfunction was noticed. The patient underwent endoscopic transnasal pituitary tumor resection and was diagnosed with a chronic expanding pituitary hematoma with calcification. The histopathological findings were very similar to those of chronic encapsulated expanding hematoma (CEEH). CEEH associated with pituitary adenomas gradually increases in size, causing visual dysfunction and pituitary dysfunction. In case of calcification, total removal is difficult due to adhesions. In this case, calcification developed within 2 years. A pituitary CEEH, even when showing calcification, should be operated on, as visual function can be fully recovered.

Sections du résumé

BACKGROUND BACKGROUND
Pituitary apoplexy (PA) is characterized by sudden headache, vomiting, visual dysfunction, anterior lobe dysfunction, and endocrine disorder due to bleeding or infarction from a pituitary adenoma. PA occurs in approximately 0.6-10% of pituitary adenomas, more commonly in men aged 50-60 years, and more frequently in nonfunctioning and prolactin-producing pituitary adenomas. Further, asymptomatic hemorrhagic infarction is found in approximately 25% of PA.
OBSERVATIONS METHODS
A pituitary tumor with asymptomatic hemorrhage was detected on head magnetic resonance imaging (MRI). Thereafter, the patient underwent head MRI every 6 months. After 2 years, the tumor was enlarged and visual dysfunction was noticed. The patient underwent endoscopic transnasal pituitary tumor resection and was diagnosed with a chronic expanding pituitary hematoma with calcification. The histopathological findings were very similar to those of chronic encapsulated expanding hematoma (CEEH).
LESSONS CONCLUSIONS
CEEH associated with pituitary adenomas gradually increases in size, causing visual dysfunction and pituitary dysfunction. In case of calcification, total removal is difficult due to adhesions. In this case, calcification developed within 2 years. A pituitary CEEH, even when showing calcification, should be operated on, as visual function can be fully recovered.

Identifiants

pubmed: 36880516
doi: 10.3171/CASE2315
pii: CASE2315
pmc: PMC10550663
doi:
pii:

Types de publication

Journal Article

Langues

eng

Références

J Neurosurg. 1961 May;18:393-7
pubmed: 13681572
Surg Neurol Int. 2013 Mar 28;4:41
pubmed: 23607063
Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82
pubmed: 19650784
Endocr Rev. 2015 Dec;36(6):622-45
pubmed: 26414232
No To Shinkei. 1966 Jul;18(7):702-9
pubmed: 5953679
Neurosurg Rev. 2013 Jul;36(3):395-402
pubmed: 23345017
J Clin Endocrinol Metab. 2010 Sep;95(9):4268-75
pubmed: 20534753

Auteurs

Fugen Takagi (F)

1Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Ryokichi Yagi (R)

1Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Takuya Kanemitsu (T)

2Department of Neurosurgery, Midorigaoka Hospital, Takatsuki City, Osaka, Japan.

Yuichiro Tsuji (Y)

3Department of Neurosurgery, Kano Genral Hospital, Osaka City, Osaka, Japan; and.

Naokado Ikeda (N)

4Department of Neurosurgery, Takeda Hospital, Kyoto City, Kyoto, Japan.

Naosuke Nonoguchi (N)

1Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Motomasa Furuse (M)

1Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Shinji Kawabata (S)

1Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Toshihiro Takami (T)

1Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Masahiko Wanibuchi (M)

1Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Classifications MeSH